Return to search results.
Complete title: A Phase 1B/2 Multicenter, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 (Ricolinostat) in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed-and-Refractory Multiple Myeloma
|Research Study Number||9056|
|Principal Investigator||Edward Libby|
Research Study Description
Phase 2: To determine the overall response rate of ACY-1215 in combination with Pomolidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Hematologic Malignancies; Lymphoproliferative Disorders; Multiple Myeloma (MM); Neoplasms; Immunoproliferative Disorders; Cardiovascular Diseases
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.